Pegzilarginase-nbln
Brand names: Loargys · Active ingredient: Pegzilarginase
In short: LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine .
What is Pegzilarginase-nbln used for?
LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction.
This indication is approved under accelerated approval based on reduction of plasma arginine . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
âš Boxed warning (FDA's strongest warning)
Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.
Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue LOARGYS and immediately initiate appropriate medical treatment, including use of epinephrine.
Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur .
Pegzilarginase-nbln dosage
•Administer LOARGYS under the supervision of a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis .
•Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment .
•Obtain a baseline plasma arginine concentration.
•Consider pre-medication with antihistamines .
The recommended starting dosage of LOARGYS is 0.1 mg/kg administered via intravenous infusion once weekly . For the recommended dosage use actual body weight.
Recommended Adjustment, Maximum Dosage, and Monitoring
To maximize the time within the normal range of 40 to 115 micromolar, dose adjustments should be aimed at achieving a pre-dose level of plasma arginine near the upper limit of normal (ULN). After four weeks of LOARGYS administration, measure pre-dose plasma arginine (168 hours after prior dose) to determine the need for dosage adjustment. If two consecutive weekly pre-dose plasma arginine measurements are not in the desired therapeutic range, increase or decrease the weekly LOARGYS dosage as follows:
•Below 50 micromolar, reduce the weekly LOARGYS dosage by 0.05 mg/kg.
•Above 150 micromolar, increase the weekly LOARGYS dosage by 0.05 mg/kg.
The maximum recommended LOARGYS dosage is 0.2 mg/kg once weekly.
Monitor plasma arginine levels (prior to LOARGYS dosing) weekly for 2 weeks after any LOARGYS dosage adjustment and as clinically indicated.
Patients may be switched from intravenous administration of LOARGYS to subcutaneous administration .
Collect samples into Immedica Pharma’s Nor-NOHA Blood Collection Tubes, which contain Nω-hydroxy-nor-Arginine (nor-NOHA), an enzyme inhibitor used to inhibit post-sampling degradation of arginine by LOARGYS, and measure arginine concentration using Immedica Pharma’s LOARGYS Arginine Assay.
LOARGYS is only available to a patient if the patient is enrolled in Study IMM-PEG-005 to obtain Immedica Pharma’s Nor-NOHA Blood Collection Tubes and LOARGYS Arginine Assay. Further information is available by contacting Immedica Pharma at 1‑844‑627‑4687.
After eight weeks of once weekly intravenous LOARGYS, patients may be switched to once weekly subcutaneous LOARGYS at the same dosage of intravenous therapy.
In the event of a severe hypersensitivity reaction (e.g., anaphylaxis), discontinue LOARGYS and immediately initiate appropriate medical treatment, including use of epinephrine. For additional recommendations in the event of a severe hypersensitivity reaction, .
In the event of a mild or moderate hypersensitivity reaction, consider treatment with antihistamines and/or corticosteroids. For intravenous administration, consider temporarily holding the infusion or slowing the infusion rate. …
How to take Pegzilarginase-nbln — instructions & advice from the label
Hypersensitivity Reactions Including Anaphylaxis:
Advise the patient and caregiver that life-threatening hypersensitivity reactions, including anaphylaxis may occur with LOARGYS treatment.
Advise the patient or caregiver that anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.
Inform the patient and caregiver of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur .
Warnings & precautions
Do not take this medicine if: None.
Life-threatening hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with enzyme replacement therapies (ERTs) including LOARGYS. Hypersensitivity reactions that were mild to moderate in severity occurred in 13% (6/48) of LOARGYS-treated patients in clinical trials . Hypersensitivity reactions have included facial swelling, rash, flushing and dyspnea. The reactions generally occurred with the first few doses, but may also occur later in treatment.
LOARGYS-treated patients who developed anti-drug antibodies (ADA) generally had a greater incidence of hypersensitivity reactions compared to those who did not develop ADA .
Anaphylaxis has occurred during the early course of ERT and after extended duration of ERT.
Administration of LOARGYS should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. Consider pre‑medication with an antihistamine. Corticosteroids can be considered in patients who have previously developed a hypersensitivity reaction. Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.
•If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LOARGYS and immediately initiate appropriate medical treatment, including use of epinephrine. Consider the risks and benefits of re-administering LOARGYS following a severe hypersensitivity reaction (including anaphylaxis). Caution should be exercised upon rechallenge. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.
•If a mild or moderate hypersensitivity reaction occurs, consider treatment with antihistamines and/or corticosteroids. …
Pegzilarginase-nbln side effects
The following adverse reactions are described below and elsewhere in the labeling:
•Hypersensitivity Reactions .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of LOARGYS was evaluated in a randomized, double-blind, placebo-controlled trial in pediatric and adult patients with ARG1-D (Trial 1). Additional safety information was derived from Trial 2, a Phase 1 open-label trial that evaluated 16 patients between the ages of 5 to 31 years to assess safety, PK and PD of LOARGYS, and Trial 3, an open-label extension including 14 patients from Trial 2.
Adverse Reactions from Trial 1 (Double-Blind Period)
A total of 21 patients between the ages of 2 and 28 years of age, at enrollment, received intravenous LOARGYS dosages up to 0.2 mg/kg once weekly and 11 patients received placebo for 24 weeks .
Table 1 summarizes the adverse reactions reported in ≥ 2 LOARGYS-treated patients and at a higher incidence in LOARGYS-treated patients compared to placebo-treated patients in Trial 1.
a Common adverse reactions were those that occurred in ≥ 2 LOARGYS-treated patients and at a higher incidence in LOARGYS-treated patients compared to placebo-treated patients. …
About this medicine
Pegzilarginase-nbln is a trimeric cobalt substituted recombinant human arginase 1 enzyme conjugated with six to twelve moles of 5 kDa monomethoxy polyethylene glycol (mPEG) per monomer. The molecular weight of pegzilarginase-nbln is approximately 224 to 344 kDa.
LOARGYS (pegzilarginase-nbln) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly yellow or slightly pink solution in a single-dose vial for intravenous infusion or subcutaneous injection. Available as 2 mg of pegzilarginase-nbln in 0.4 mL or 5 mg of pegzilarginase-nbln in 1 mL.
Each 1 mL contains 5 mg pegzilarginase-nbln, dibasic potassium phosphate (0.7 mg), glycerin (15 mg), monobasic potassium phosphate (0.14 mg), sodium chloride (2.92 mg), Water for Injection, USP, and hydrochloric acid and/ or sodium hydroxide to adjust pH to 7 to 7.6 The resultant concentration is 5 mg/mL.
How it works: ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d5ceabf2-43a0-4746-9371-d98a39cf6cfc. Read the full official label on DailyMed.